Alk-positive Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Alk-positive Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) [Phase 1]
Phase 1 study evaluating gilteritinib in adults with advanced ALK-positive non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context [NA]
A clinical trial update announcing the ongoing recruitment of a real-world study evaluating lorlatinib in untreated ALK-positive non-small c…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC [Phase 3]
A Phase 3 trial of neladalkib (NVL-655) for tyrosine kinase inhibitor–naive patients with advanced ALK-positive non-small cell lung cancer i…
-
CLINICAL_TRIALS research · 2025-06-12Clinical Trial Update: Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer [Phase 2]
A phase 2 neoadjuvant trial of WX-0593 for resectable ALK-positive or ROS1-positive non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-26Clinical Trial Update: ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study
A multi-institution retrospective study evaluating digital pathology outcome prediction in ALK-positive non-small cell lung cancer treated w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study
A real-world study is being conducted to determine the incidence and risk factors of CNS adverse events in ALK-positive advanced non-small c…
-
CLINICAL_TRIALS research · 2024-05-13Clinical Trial Update: Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels [Phase 4]
A Phase 4 trial is comparing standard-dose alectinib to dose-adjusted dosing based on blood levels in ALK-positive non-small cell lung cance…